Amonafide

Amonafide
Clinical data
Trade namesXanafide, Quinamed
ATC code
  • none
Identifiers
  • 5-amino-2-[2-(dimethylamino)ethyl]-1H-benzo[de]isoquinoline-1,3(2H)-dione
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC16H17N3O2
Molar mass283.331 g·mol−1
3D model (JSmol)
  • O=C2c1c3c(ccc1)cc(cc3C(=O)N2CCN(C)C)N
  • InChI=1S/C16H17N3O2/c1-18(2)6-7-19-15(20)12-5-3-4-10-8-11(17)9-13(14(10)12)16(19)21/h3-5,8-9H,6-7,17H2,1-2H3 checkY
  • Key:UPALIKSFLSVKIS-UHFFFAOYSA-N checkY
  (verify)

Amonafide (originally AS1413) (INN, trade names Quinamed and Xanafide) was a drug that was being studied in the treatment of cancer. It belongs to a novel family of chemotherapeutic drugs called Naphthalimides and is a potential topoisomerase inhibitor and DNA intercalator.

It was being developed as an anti-cancer therapy by Antisoma.

As of 2008, it is in Phase III clinical trials. e.g. In March 2010 it is Phase III trial against secondary acute myeloid leukaemia (AML). In June 2010, it gained an FDA Fast Track Status for the treatment of Secondary Acute Myeloid Leukaemia.[citation needed]

See also